Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a wearable sensor replace Finger-Sticks for hospital diabetes care?

NCT ID NCT04845685

Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests whether a continuous glucose monitor (CGM) worn on the skin can accurately track blood sugar levels in hospitalized patients with diabetes who have just had major transplant surgery. The CGM measures glucose every 1-5 minutes, and researchers compare its readings to standard finger-stick tests. The goal is to see if the device is reliable enough to help prevent dangerous blood sugar highs and lows in a hospital setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous Glucose Monitor (CGM) device (Dexcom G6 PRO)
What this could lead to
If successful, this could show that CGMs are reliable enough to replace frequent finger-stick tests in hospitalized patients, potentially improving safety and reducing nursing workload.
What could go wrong
This is a small, early-stage accuracy study, not a large trial testing patient outcomes. The device may not perform as well in sick, post-surgery patients as it does in outpatient settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with Type 1 or 2 Diabetes Mellitus. * Patients 18 years of age or older. * Admitted for deceased donor renal transplant surgery, pancreas transplant surgery, heart transplant surgery, liver transplant surgery and lung transplant surgery. * Anticipated minimum of 72h hospital stay. * Patients on insulin therapy (IV, SQ) post-surgery. Exclusion Criteria: * Active COVID-19 infection. * Pregnant or lactating female. * Altered Mental Status at the time of sensor placement (sensor will be placed once mental status will improve). * Inability to provide informed consent. * Patients taking more than 4 g of acetaminophen in 24 hours or more than 1 gm every 6 hours. Patients with skin lesions at the application site that may interfere with placement of the sensor. Patients with known allergy to medical grade adhesive.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus

Contacts and locations

Locations

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.